Moderna Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Moderna Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH283055D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Moderna Therapeutics Inc (Moderna Therapeutics) carries out the development of a novel class of drugs made of messenger RNA (mRNA). Its pipeline includes various drug modalities such as vaccines, intracellular and transmembran, intratumoral, secreted antibodies and secreted proteins. Moderna Therapeutics built a mRNA therapeutics platform, is an in vivo drug technology which produces human proteins, antibodies and novel protein constructs inside patient cells, which are secreted or intracellularly active. The company has collaboration with Alexion, AstraZeneca, Merck, DARPA, Institut Pasteur, Karolinski Institutet, and Karolinska University Hospital for the development of clinical programs leveraging its mRNA therapeutics platform. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Moderna Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Moderna Therapeutics Raises USD450 Million in Venture Financing 12

Moderna Therapeutics Raises Additional USD25 Million in Venture Financing 13

Onkaido Therapeutics To Raise US$20 Million In Venture Financing 14

Moderna Therapeutics Raises US$110 Million In Venture Financing 14

Moderna Therapeutics Raises US$40 Million In Series A Financing 15

Partnerships 16

Moderna Therapeutics Enters into Agreement with Charles River Labs 16

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 17

Moderna Therapeutics Enters into Agreement with Pharmaceutical Product Development 18

Moderna Therapeutics Enters into Research Agreement with Institut Pasteur 18

Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 19

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 20

AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 21

Licensing Agreements 23

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Merck Enters into Licensing Agreement with Moderna Therapeutics 24

Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 25

Equity Offering 26

Moderna Therapeutics Raises USD474 Million in Private Placement of Shares 26

AstraZeneca Invests USD140 Million in Moderna Therapeutics 27

Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 27

Moderna Therapeutics Inc-Key Competitors 29

Key Employees 30

Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Corporate Communications 32

Feb 22, 2017: Moderna Appoints Israel Ruiz to its Board of Directors 32

Sep 13, 2016: Melissa Moore to Join Moderna as chief Scientific Officer 34

Apr 04, 2016: Moderna Announces Appointment of Dr. Michael Watson as President of Valera 35

Mar 28, 2016: Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer 36

Government and Public Interest 37

Jan 12, 2016: Moderna Therapeutics, Through Valera, its Infectious Disease Venture, Announces Initial Grant of up to $20 Million to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection 37

Other Significant Developments 38

Jan 09, 2017: Moderna Provides Pipeline and Full-Year Corporate Update 38

Jul 26, 2016: Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration 43

Jan 11, 2016: Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 1

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Moderna Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Moderna Therapeutics Raises USD450 Million in Venture Financing 12

Moderna Therapeutics Raises Additional USD25 Million in Venture Financing 13

Onkaido Therapeutics To Raise US$20 Million In Venture Financing 14

Moderna Therapeutics Raises US$110 Million In Venture Financing 14

Moderna Therapeutics Raises US$40 Million In Series A Financing 15

Moderna Therapeutics Enters into Agreement with Charles River Labs 16

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 17

Moderna Therapeutics Enters into Agreement with Pharmaceutical Product Development 18

Moderna Therapeutics Enters into Research Agreement with Institut Pasteur 18

Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 19

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 20

AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 21

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Merck Enters into Licensing Agreement with Moderna Therapeutics 24

Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 25

Moderna Therapeutics Raises USD474 Million in Private Placement of Shares 26

AstraZeneca Invests USD140 Million in Moderna Therapeutics 27

Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 27

Moderna Therapeutics Inc, Key Competitors 29

Moderna Therapeutics Inc, Key Employees 30

Moderna Therapeutics Inc, Other Locations 31

Moderna Therapeutics Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Moderna Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com